1. Home
  2. IDYA vs NVG Comparison

IDYA vs NVG Comparison

Compare IDYA & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$31.40

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Nuveen AMT-Free Municipal Credit Income Fund

NVG

Nuveen AMT-Free Municipal Credit Income Fund

HOLD

Current Price

$11.99

Market Cap

2.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
NVG
Founded
2015
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.7B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IDYA
NVG
Price
$31.40
$11.99
Analyst Decision
Strong Buy
Analyst Count
16
0
Target Price
$51.21
N/A
AVG Volume (30 Days)
824.6K
641.4K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
4.65%
EPS Growth
61.90
N/A
EPS
N/A
N/A
Revenue
$218,710,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$191.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3024.43
N/A
52 Week Low
$13.45
$11.00
52 Week High
$39.28
$13.59

Technical Indicators

Market Signals
Indicator
IDYA
NVG
Relative Strength Index (RSI) 44.31 22.42
Support Level $29.15 $11.51
Resistance Level $35.47 $12.51
Average True Range (ATR) 1.47 0.14
MACD -0.26 -0.08
Stochastic Oscillator 30.38 4.36

Price Performance

Historical Comparison
IDYA
NVG

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About NVG Nuveen AMT-Free Municipal Credit Income Fund

Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.

Share on Social Networks: